Target intelligence / Profile preview

Mucin-degrading metalloprotease YghJ (YghJ)

Target
YghJ
Molecular classification
Enzyme, Metalloprotease, Lipoprotein, Bacterial antigen
01

Overview

Mucin-degrading metalloprotease YghJ, also known as SslE, is a large secreted lipoprotein and a critical virulence factor found in various pathogenic Escherichia coli strains, including Enterotoxigenic E. coli (ETEC) and Extraintestinal Pathogenic E. coli (ExPEC) (Luo et al., 2014, PMID: 24818661). It functions as a zinc-metalloprotease belonging to the M60-like family, specifically targeting and degrading host mucin glycoproteins (such as MUC2 and MUC3) that constitute the protective mucus barrier of the intestinal and extraintestinal tracts (Nesta et al., 2014, PMID: 24639449). By breaking down this barrier, YghJ facilitates bacterial penetration and subsequent adhesion to the underlying epithelial cells, which is essential for colonization and the delivery of toxins (Luo et al., 2014, PMID: 24818661). The protein undergoes O-linked glycosylation, a post-translational modification that may influence its stability and role as a surface-exposed antigen (UniProt, P0CK95). Due to its high conservation across diverse E. coli pathotypes and its indispensable role in infection, YghJ is a primary target for the development of broadly protective vaccines and therapeutic antibodies (Nesta et al., 2014, PMID: 24639449). Experimental studies have demonstrated that antibodies targeting YghJ can effectively neutralize its mucinase activity and reduce bacterial load in vivo (Fleckenstein et al., 2014, PMID: 24933307).

Other names
SslESecreted sticky lipoprotein EM60-like metalloproteaseECOP_03810AcpP-like protein
02

Mechanism of action

Neutralization of the protease activity to prevent the degradation of the host's protective mucus layer, thereby inhibiting bacterial access and adhesion to the underlying epithelial cells (Nesta et al., 2014, PMID: 24639449).

03

Biological functions

Mucin degradationProteolysisBacterial colonizationBiofilm formationHost-pathogen interaction
04

Disease associations

InfectionDiarrheaUrinary tract infectionNeonatal meningitisSepsis
05

Safety considerations

Potential impact on commensal Escherichia coli populationsTheoretical risk of cross-reactivity with host metalloproteasesImmunogenicity and stability of the glycosylated form in vaccine formulations
06

Interacting drugs

Experimental ETEC vaccine candidates

1 more in the full profile.

07

Biomarkers

YghJ protein expression in clinical isolatesAnti-YghJ IgG/IgA antibody titers (Luo et al., 2014, PMID: 24818661)

Beyond the preview

Go deeper on Mucin-degrading metalloprotease YghJ (YghJ).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mucin-degrading metalloprotease YghJ (YghJ).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call